Bremelanotide / PT-141: what do human clinical studies show?

This Research Library page summarizes independently published research on Bremelanotide / PT-141. For each study, the research model, key finding, and main limitation are provided.

Study 1

Level of evidence: Human research - phase 3 RCTs

Subject: Hypoactive sexual desire disorder in premenopausal women.

Key finding: Statistical improvements in sexual desire and related distress were reported; nausea was common.

Main limitation: Applies to the studied approved pharmaceutical formulation and specific population.

Source: Original publication via PubMed

Study 2

Level of evidence: Human research - RCT

Subject: Sexual dysfunction in premenopausal women.

Key finding: The study reported signals of efficacy and described dose-dependent side effects.

Main limitation: Specific diagnosis and study population; not applicable to all forms of sexual dysfunction.

Source: Original publication via PubMed

Study 3

Level of evidence: Human research - double-blind, placebo-controlled

Subject: Intranasal PT-141 in healthy men and men with mild to moderate erectile dysfunction.

Key finding: Pharmacokinetics, erectile response, and side effects were investigated.

Main limitation: Older intranasal formulation; not equivalent to other routes or commercial research products.

Source: Original publication via PubMed

Scientific distinction: Research on a molecule, research model, or pharmaceutical formulation does not constitute evidence for the efficacy, safety, purity, or suitability of a commercial Peptidera product. This page does not provide treatment or usage advice.

Header image: illustrative visualization, not a research result.